Apogee Therapeutics, Inc. (APGE) Discusses 52-Week Phase 2 APEX Data for Zumilokibart in Moderate to Severe Atopic Dermatitis - Slideshow By Iron Striker · March 23, 2026 · 1 min read apgesa transcripts Source: seekingalpha.com